Bone loss. Therapeutic approaches for preventing bone loss in inflammatory arthritis.
Inflammatory arthritides are commonly characterized by localized and generalized bone loss. Localized bone loss in the form of joint erosions and periarticular osteopenia is a hallmark of rheumatoid arthritis, the prototype of inflammatory arthritis. Recent studies have highlighted the importance of receptor activator of nuclear factor-kappa B ligand (RANKL)-dependent osteoclast activation by inflammatory cells and subsequent bone loss. In this article, we review the pathogenesis of inflammatory bone loss and explore the possible therapeutic interventions to prevent it.
Rehman
Q
Q
University of California, San Francisco, CA 94110, USA.
Lane
N E
NE
D001172:Arthritis, Rheumatoid / Q000276:immunology / Q000473:pathology* / Q000628:therapy*; D016723:Bone Remodeling / Q000276:immunology; D002352:Carrier Proteins / Q000096:biosynthesis; D006801:Humans; D008562:Membrane Glycoproteins / Q000096:biosynthesis; D010010:Osteoclasts / Q000378:metabolism; D010024:Osteoporosis / Q000517:prevention & control*; D053245:RANK Ligand; D053246:Receptor Activator of Nuclear Factor-kappa B
D002352:Carrier Proteins; D008562:Membrane Glycoproteins; D053245:RANK Ligand; D053246:Receptor Activator of Nuclear Factor-kappa B; C505686:TNFRSF11A protein, human; C505688:TNFSF11 protein, human